Skip to main content

Table 4 Diagnostic performance of dedicated vs. standard protocol

From: The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review

First author, year

 

Sensitivity (95 % CI)

Specificity (95 % CI)

NPV (95 % CI)

PPV (95 % CI)

Accuracy (95 % CI)

Dedicated to axilla

T1w/T2w/DCE

  Yoshimura et al. 1999

 

79.0 %

93.0 %

87.0 %

89.0 %

88.0 %

  Kvistad et al. 2000

 

83.0 %

90.0 %

90.0 %

83.0 %

88.0 %

  Li et al. 2014

 

94.6 %

98.5 %

95.0 %

98.2 %

Not reported

 

Median

88.4 %

93.0 %

94.7 %

89.0 %

86.5 %

 

Range

79–94.6 %

90–98.5 %

87–95 %

83.0–98.2 %

88.0 %

T2*w USPIO

  Michel et al. 2002

Disease based

82.0 %

100 %

78.0 %

100,0 %

89.0 %

Two readers lymph node based

73.083.0 %

96.097.0 %

97.098.0 %

71.074.0 %

94.095.0 %

  Harada et al. 2006

Combined study

86.4 %

97.5 %

96.1 %

91.1 %

95.0 %

Postcontrast alone

84.7 %

96.8 %

95.6 %

88.5 %

94.0 %

 

Median

83.0 %

97.0 %

95.9 %

89.8 %

94.3 %

Range

73.0–86.4 %

96.0–100 %

78.0–98.0 %

71.0–100 %

89.0–95.0 %

 

Median

84.7 %

96.8 %

95.0 %

89.0 %

91.5 %

Range

73–94.6 %

90.0–100.0 %

78.0–98.0 %

71.0–100 %

88.0–95.0 %

Covering breast and axilla

T1w/T2w/DCE

  Orguc et al. 2012

 

89.0 %

14.0 %

80.0 %*

21.4 %*

Not reported

  He et al. 2012

Overall

33.386.5 %

95.298.2 %

1.916.7 %

66.782.6 %

Not reported

Early stage enhancement rate**

97.0 %

73.5 %

99.5 %*

30.5 %*

Not reported

  Scaranelo et al. 2012

 

88.4 % (76–95)

82.4 % (71–90)

94.7 %*

69.4 %*

85.0 % (77–91)

  Hwang et al. 2013

 

47.8 %

88.7 %

82.6 %

60.2 %

77.9 %

  Hieken et al. 2013

N0 with N0i+

54.2 % (46.661.6)

78.2 % (73.282.5)

75.7 % (70.780.1)

57.7 % (49.965.2)

69.7 %

N0 without N0i+

57.2 % (49.164.9)

78.2 % (73.282.5)

78.9 % (74.083.2)

56.2 % (48.263.9)

71.3 %

  Abe et al. 2013

 

60.0 %

79.0 %

81.0 %

59.0 %

74.0 %

  An et al. 2014

 

67.5 %

78.0 %

79.2 %

65.9 %

74.0 %

 

Median

60.0 %

78.6 %

80.0 %

59.0 %

74.0 %

Range

33.3–97.0 %

14.0–98.5 %

1.9–99.5 %

21.4–92.6 %

69.7–85.0 %

DWI

  Fornasa et al. 2012

Cutoff <1.09 × 10−3 mm2/s

94.7 %

91.7 %

95.7 %

90.0 %

93.0 %

  He et al. 2012

Cutoff <1.35 × 10−3 mm2/s

97.0 %

54.5 %

99.4 %*

20.4 %*

Not reported

  Scaranelo et al. 2012

No cutoff value

83.9 % (73–91)

77.0 % (65–86)

90.9 %*

60.5 %*

80.0 % (72–86)

  Luo et al. 2013

Cutoff <0.89 × 10−3 mm2/s

82.2 %

82.4 %

77.8 %

86.1 %

82.3 %

ADC ratio*** ≤1.097

84.4 %

88.2 %

81.1 %

90.5 %

86.1 %

  Kamitani et al. 2013

Cutoff <1.05 × 10−3 mm2/s

53.8 %

86.9 %

85.9 %

56.0 %

79.1 %

Cutoff <1.22 × 10−3 mm2/s

75.6 %

71.1 %

90.2 %

54.3 %

Not reported

  Basara et al. 2013

Cutoff <1.49 × 10−3 mm2/s

95.6 %

30.3 %

95.6 %

30.3 %

Not reported

 

Median

84.2 %

79.7 %

90.6 %

58.3 %

82.3 %

Range

53.8–97.0 %

30.3–91.7 %

77.8–99.4 %

20.4–90.5 %

79.1–93.0 %

 

Median

82.0 %

78.2 %

82.6 %

59.0 %

79.1 %

Range

33.3–97.0 %

14.0–98.5 %

1.9–95.7 %

30.3–92.6 %

69.7–93.0 %

  1. T1w T1 weighted, T2w T2 weighted, T2*w T2* weighted, N+ nodal stage positive, N0 no regional lymph node metastasis, N0i + isolated tumour cells, DCE dynamic contrast enhanced, DWI diffusion-weighted imaging, T2*w T2* weighted, USPIO ultrasmall superparamagnetic iron oxide, ADC apparent diffusion coefficient, CI confidence interval
  2. *Calculated parameters, **diagnostic parameter with a combination of the highest senstivity and NPV, ***ADC ratio = ratio of lymph node ADC value to the primary tumour ADC value